Study Finds 25-Fold Death Risk After Malnutrition in Seniors on Zepbound
Updated
Updated · health.yahoo.com · Jul 14
Study Finds 25-Fold Death Risk After Malnutrition in Seniors on Zepbound
3 articles · Updated · health.yahoo.com · Jul 14
Summary
Nearly 30,000 U.S. adults 65 and older on Zepbound showed sharply higher death risks once frailty-related problems appeared, including a roughly 25-fold increase after malnutrition, six-fold after dehydration and 12-fold after muscle wasting.
Those conditions were uncommon overall—malnutrition affected 1.6%, dehydration 3%, muscle decline 0.16% and appetite loss 4.75%—but became more likely with older age, multiple illnesses and weight loss above 20%.
Frailty signals in tirzepatide users typically emerged after about six months, and the researchers said they may mark deteriorating health rather than prove the drug caused the adverse outcomes.
The findings land as Medicare Part D began covering obesity GLP-1 drugs on July 1 with a $50 monthly copay, potentially opening access to 3 million to 4 million older adults.
A new study links Zepbound to a 25-fold death risk in frail seniors. Is the drug the cause or just a warning sign?
With Medicare now covering obesity drugs, are we overlooking a deadly frailty risk for seniors who lose weight too quickly?
Tirzepatide (Zepbound) in Seniors: Elevated Frailty, Malnutrition, and Mortality Risks Demand Proactive Monitoring
Overview
A recent study by the U.S. analytics firm nference highlights that older adults taking Zepbound, Eli Lilly’s GLP-1 obesity drug, may face a higher risk of frailty and related health problems. The research compared different groups of seniors and found that conditions like malnutrition and muscle loss can occur in those using Zepbound, especially if they already have underlying health issues. These findings suggest that frailty in patients may not be caused directly by the drug, but close supervision is still needed to ensure safety and address any adverse outcomes early.